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Introduction
Silver nanoparticles (AgNP) are widely used 
for their antimicrobial activity and are found 
in textiles, cosmetics, food, and medical 
supplies. AgNP are currently being considered 
for use as anticancer agents (Wei et al. 2015). 
Approximately 50% of all nanoparticles in 
commercial use today are composed of silver 
(Project on Emerging Nanotechnologies 
2015). Exposure to AgNP can occur through 
dermal absorption, oral ingestion, or inhala-
tion. Inhalation of AgNP may occur during 
manufacturing, cloud seeding, or spraying 
for wound treatment, or through the use of 
AgNP as an aerosol disinfectant (Genter et al. 
2012) or over-the-counter homeopathic spray 
for treatment of respiratory infections (Silver 
Lungs 2009; Silver Edge 2012). Because of 
their small size, AgNP can easily penetrate 
into the deep lung, which possesses an 
immense surface area for deposition, and can 
potentially transport to the systemic circula-
tion. AgNP can also enter the nasal cavity 
and translocate to the brain via the olfactory 
epithelium, a direct connection between the 
nose and brain (Kovács 2004).
Previous studies have shown that nano-
particles, viruses, and molecules can bypass 
the blood–brain barrier and be transported 
from the olfactory epithelium in the nasal 
cavity to the olfactory bulb (OB) in the 
forebrain (Illum 2000; Mistry et al. 2009b). 
Three possible pathways have been suggested: 
a) transcellular transport across sustentacular 
cells of the olfactory epithelium, b) para-
cellular transport through junctions of the 
olfactory epithelium, or c) intracellular trans-
port through axonal movement via olfac-
tory nerve fascicles to the synaptic junctions 
within the OB (Illum 2000; Shepherd 1994). 
Nanoparticle translocation along axons of 
olfactory nerve fascicles and accumulation in 
the OB have been previously studied (Aschner 
2009; De Lorenzo 1960; Elder et al. 2006, 
2009; Hopkins et al. 2014; Oberdörster et al. 
2004; Patel et al. 2011).
AgNP toxicity has been associated with 
the formation of Ag cations (Ag+), biochemi-
cally active agents (Brett 2006) that cause 
cytotoxic (Chernousova and Epple 2013; Loza 
et al. 2014; Xiu et al. 2012) and inflamma-
tory responses (Wang et al. 2014) indepen-
dent of the parent AgNP. The toxicity of Ag+ 
may be due to its interaction in biochemical 
processes with proteins, nucleic acids, and cell 
membranes (Chernousova and Epple 2013). 
Smaller (20 nm) AgNP were found to have 
faster dissolution rates and Ag+ formation 
than larger (110 nm) AgNP (Davidson et al. 
2015; Wang et al. 2014).
Human health effects from AgNP 
exposure have been reported following dermal 
or oral administration (Gavanji et al. 2013); 
however, to the best of our knowledge, there 
are currently no published peer-reviewed 
studies that discuss the effects of AgNP inha-
lation in humans. Inhalation studies with 
animals demonstrated deposition of Ag in 
the lung and translocation of these nanopar-
ticles to other organs (Anderson et al. 2015; 
Braakhuis et al. 2014; Genter et al. 2012; Ji 
et al. 2007; Sung et al. 2009). Toxic responses 
included epithelial erosion, proteinaceous 
exudates, and presence of inflammatory 
cells in the nasal cavity (Genter et al. 2012), 
airways and alveoli (Braakhuis et al. 2014; 
Sung et al. 2009), and consequent bile duct 
hyperplasia in the liver (Sung et al. 2009). 
The magnitude of these changes appears to 
be dependent on the dose or the size of the 
AgNP used, or on a combination of both 
(Braakhuis et al. 2014; Sung et al. 2009).
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Background: Silver nanoparticles (AgNP) are present in personal, commercial, and industrial 
products, which are often aerosolized. Current understanding of the deposition, translocation, and 
health-related impacts of AgNP inhalation is limited.
oBjectives: We determined a) the deposition and retention of inhaled Ag in the nasal cavity from 
nose-only exposure; b) the timing for Ag translocation to and retention/clearance in the olfactory 
bulb (OB); and c) whether the presence of Ag in the OB affects microglial activity.
Methods: Male Sprague-Dawley rats were exposed nose-only to citrate-buffered 20- or 110-nm 
AgNP (C20 or C110, respectively) or citrate buffer alone for 6 hr. The nasal cavity and OB were 
examined for the presence of Ag and for biological responses up to 56 days post-exposure (8 weeks).
results: The highest nasal Ag deposition was observed on Day 0 for both AgNP sizes. Inhalation 
of aerosolized C20 resulted in rapid translocation of Ag to the OB and in microglial activation at 
Days 0, 1, and 7. In contrast, inhalation of C110 resulted in a gradual but progressive transport of 
Ag to and retention in the OB, with a trend for microglial activation to variably be above control.
conclusions: The results of this study show that after rats experienced a 6-hr inhalation exposure 
to 20- and 110-nm AgNP at a single point in time, Ag deposition in the nose, the rate of transloca-
tion to the brain, and subsequent microglial activation in the OB differed depending on AgNP size 
and time since exposure.
citation: Patchin ES, Anderson DS, Silva RM, Uyeminami DL, Scott GM, Guo T, 
Van Winkle LS, Pinkerton KE. 2016. Size-dependent deposition, translocation, and microglial 
activation of inhaled silver nanoparticles in the rodent nose and brain. Environ Health Perspect 
124:1870–1875; http://dx.doi.org/10.1289/EHP234
Size-dependent activity of AgNP in nose and brain
Environmental Health Perspectives • volume 124 | number 12 | December 2016 1871
The objectives of this study were to deter-
mine a) the deposition and retention of Ag in 
the nasal cavity following inhalation exposure; 
b) the timing for Ag translocation and reten-
tion/clearance in the OB; and c) whether the 
presence of Ag in the OB affects the activity of 
microglial cells, the resident macrophages of the 
OB and the brain. Nasal cavities and OBs in 
this study were obtained from the same animals 
used in the study by Anderson et al. (2015), in 
which a single acute inhalation dose of 20- or 
110-nm AgNP (C20 or C110, respectively) 
was delivered over a period of 6 hr, and biolog-
ical samples were obtained immediately after 
exposure (T0) and at 1 (T1), 7 (T7), 21 (T21), 
and 56 (T56) days post-exposure.
Methods
Particles
AgNP [20 or 110 nm in diameter (nano-
Composix, Inc., San Diego, CA)] were 
suspended in citrate buffer (Fisher Scientific, 
Pittsburgh, PA). The AgNP were procured, 
characterized, and supplied by the National 
Institute of Environmental Health Sciences 
(NIEHS) Centers for Nanotechnology 
Health Implications Research (NCNHIR) 
Consortium [National Institutes of Health 
(NIH) 2015]. Citrate stabilized the particles by 
creating electrostatic repulsion, thus preventing 
AgNP aggregation and enabling control of 
the final particle size (Tolaymat et al. 2010). 
Physicochemical characterization of the AgNP 
has been described by Anderson et al. (2015), 
Silva et al. (2015), and Wang et al. (2014).
Animals
Ten- to 12-week-old male Sprague Dawley rats 
(Harlan Laboratories, Livermore, CA) were 
used to maintain consistency with other studies 
(Anderson et al. 2015; Ji et al. 2007; Silva et al. 
2015; Sung et al. 2009). Upon arrival, rats 
were randomly assigned to one of three groups: 
a) C20-, b) C110-, or c) citrate control–treated 
(n = 8 per AgNP treatment group per time 
point, and n = 8 for citrate control). The rats 
were allowed to acclimate for 1 week before 
AgNP exposure and were housed two per 
cage and given access ad libitum to water and 
a standard laboratory rodent diet (Purina 
Mills, St. Louis, MO) except during exposure 
periods. Animals were handled under protocols 
in accordance with the Guide for the Care and 
Use of Laboratory Animals (National Research 
Council 2011) and the Institutional Animal 
Care and Use Committee of the University of 
California (UC), Davis.
Aerosolization of AgNP
Rats were acclimated in inhalation exposure 
tubes (Teague Enterprises, Woodland, CA) 
for 1 week prior to the scheduled exposure 
to simulate exposure conditions. Animals 
were trained to enter and remain in the 
exposure tubes until released. Time in the 
tube increased up to 6 hr at a gradual rate 
over the training week. This training served to 
minimize/prevent confinement stress during 
the actual AgNP aerosol exposure period.
Rats were exposed via nose-only inhala-
tion to C20, C110, or citrate buffer for 6 hr. 
The aerosolization regimen has been previously 
described (Anderson et al. 2015). Briefly, a 
6-jet collision nebulizer (Mesa Labs, Waltham, 
MA) was used to aerosolize the AgNP suspen-
sions into fine droplets. Water was removed 
from the droplets using two TSI diffusion 
dryers (TSI, Shoreview, MN), and particle 
charge was neutralized with a Krypton-85 
source. Samples were collected throughout the 
exposure period to characterize the aerosol with 
gravimetric, X-ray fluorescence (XRF), cascade 
impactor, transmission electron microscope 
(TEM), and real-time size mobility particle 
scanner (SMPS) measurements, as previously 
described by Anderson et al. (2015). Airborne 
particle number was also calculated based on 
the airborne concentration of Ag collected by 
XRF analysis. Estimated Ag deposition in the 
nose normalized to surface area of the rat nasal 
epithelium was 4 μg/cm2 or 1 μg/cm2 after 
exposure to aerosolized suspensions of C20 
or C110, respectively. This dose was selected 
to approximate human exposure after 1 day 
of light work in a worst-case occupational 
scenario, based on assumptions and calculations 
described in detail in Supplemental Material, 
“Relating experimental rodent inhalation of 
AgNP to human occupational exposure.”
Necropsy and Tissue Collection
Biological samples were collected at all post-
exposure time points. All rats were anesthe-
tized by intraperitoneal injection of sodium 
pentobarbital (120 mg/kg) and euthanized via 
exsanguination. The nasal epithelia and OBs 
from five animals per group were collected 
and frozen in liquid nitrogen for silver detec-
tion via inductively coupled plasma mass 
spectrometry (ICP-MS). In addition, the OBs 
from three rats per group were fixed in 4% 
paraformaldehyde for silver detection via auto-
metallography, and sections of these fixed OBs 
were also used for microglial examination and 
cytokine expression assays.
Preparation of Tissue Sections
To detect silver by ICP-MS, the entire animal 
head was cut sagittally to expose the nasal 
epithelium. All the strippable epithelium, 
including the septal and turbinate walls, was 
collected to maintain collection consistency 
between rats.
The nasal epithelia and whole OBs were 
placed into liquid nitrogen in 15-mL conical 
tubes. Frozen tissues were lyophilized using 
LabconcoFreeZone 2.5 (Kansas City, MO) 
for 48 hr, after which tissue weights were 
determined. The tissues were subsequently 
digested using equal parts of 70% trace metal–
grade nitric acid (Fisher Scientific, Waltham, 
MA) and 30% hydrogen peroxide (EMD 
Millipore, Billerica, MA). Digestion in nitric 
acid proceeded at 70°C for 2 hr, and then 
the samples were cooled to room temperature 
(25°C) for 1 hr. Subsequent digestion in an 
equal volume of hydrogen peroxide proceeded 
at 70°C for 15 hr followed by cooling to 
room temperature. All samples were brought 
to a known volume and diluted 5:1 with 
Milli-Q® water.
Samples were analyzed at the UC Davis 
Interdisciplinary Center for Plasma Mass 
Spectrometry using an Agilent 7500CE 
ICP-MS (Agilent Technologies, Palo Alto, 
CA). Silver concentration (micrograms Ag/
gram tissue) was calculated from the known 
tissue weight (grams), sample volume (millili-
ters), and measured Ag content (nanograms/
milliliter). The mean and standard error of 
the silver concentration were calculated, 
and statistical differences were compared 
between C20- or C110-treated and citrate 
control groups at each time point. The hypo-
thetical number of AgNP in the nose and 
in the OB was also estimated from the mass 
of Ag detected by ICP-MS and normalized 
to known tissue weight. For these calcula-
tions, we assumed that the AgNP main-
tained a spherical shape with no dissolution 
throughout the post-exposure period.
For silver detection via autometal lography, 
nasal sections were deparaffinized with 
toluene, hydrated in decreasing concentrations 
of ethanol, and stained with equal volumes of 
developer and enhancer from a silver enhance-
ment kit for light and electron microscopy 
(Ted Pella Inc., Redding, CA) for 15 min. 
Sections were then dehydrated in increasing 
concentrations of ethanol and toluene and 
coverslipped with ClearMount™ permanent 
mounting medium (Thermo Fisher Scientific). 
All images were collected using a Zeiss 
AxioLab.A1 microscope.
Microglial Activation and TNF-α 
Detection in the Olfactory Bulb
For microglial examination and cytokine 
expression, OBs were fixed in 4% paraformal-
dehyde for 7 days and embedded in paraffin 
in a sagittal orientation. Five-micrometer-thick 
sections were cut, deparaffinized with toluene, 
hydrated in decreasing concentrations of 
ethanol, and rinsed with phosphate-buffered 
saline with Tween (PBST; Sigma Aldrich, St. 
Louis, MO) before antigen retrieval. Slides 
were immersed in citric acid (Thermo Fisher 
Scientific; pH = 6) for 30 sec at 125°C for 
antigen retrieval, followed by 10 sec at 85°C. 
Sections were then cooled for 15 min, rinsed 
with PBST for 3 min and with 3% hydrogen 
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peroxide for 5 min, washed in PBST three 
times at 3 min each; the PBST washes were 
followed by a nonspecific block, Protein 
Block (Dako, Carpinteria, CA), for 30 min at 
20°C. The sections were then incubated with 
the primary antibody, anti-ionized calcium-
binding adapter molecule 1 (anti-Iba1; Abcam 
Inc., Cambridge, MA), for 3 hr to visualize 
microglial cells in a state of rest or activa-
tion or with anti-tumor necrosis factor alpha 
(anti-TNF-α; Abcam Inc.) for 1 hr at 20°C. 
Sections were washed with PBST three times 
for 3 min each, then incubated in secondary 
antibody, biotinylated affinity-purified goat 
anti-rabbit immunoglobulin G (IgG; Vector 
Laboratories, Burlingame, CA), for 1 hr at 
20°C or in horseradish peroxidase (HRP)-
labeled polymer (rabbit) (Dako) for 30 min 
at 20°C. The sections were again washed with 
PBST for 5 min, incubated with Avidin/Biotin 
Complex (Vector Laboratories) for 30 min at 
20°C, and rinsed with PBST again three times 
for 5 min each. The sections were then incu-
bated with 3,3′-diaminobenzidine (DAB) and 
substrate (Dako) for 5 min, counterstained 
with Harris’s Hematoxylin (MasterTech, 
Inc., Lodi, CA), and coverslipped with 
ClearMount™ permanent mounting medium 
(Thermo Fisher Scientific).
Microglial morphology was observed to 
determine whether they were resting or acti-
vated. Briefly, resting microglia were defined 
as cells with at least two highly branched 
(ramified) processes extending at least twice the 
length of a highly elliptical nucleus. Activated 
microglia were defined as cells with significantly 
shortened branching processes extending from 
a slightly enlarged cell nucleus (Figure 1). 
Microglia were counted in 10 randomly 
sampled, nonoverlapping fields per histological 
section per animal and were observed at an 
objective magnification of 20× using a Zeiss 
AxioLab.A1 microscope. Resting and activated 
microglia were also counted in identical histo-
logical fields for each animal to a total of 50 
cells/animal, and the ratio of active to total cells 
was calculated. The mean value and percent 
difference (compared with control) were deter-
mined for each exposure group at each time 
point. The incidence of TNF-α staining in 
the OB was measured using ImageJ (Rasband 
1997–2016), and images were acquired with a 
5× objective on the same Zeiss microscope. The 
intensity of TNF-α staining within total areas 
of expression was determined for each exposure 
group at each time point. Three animals per 
AgNP treatment group per time point were 
examined along with six control animals.
Silver Transport Analysis
The percentage of Ag translocated to the OB 
via the olfactory region of the nasal cavity at 
T0 for C20 and at T56 for C110 was calcu-
lated. Based upon the computational fluid 
dynamics model proposed by Garcia and 
Kimbell (2009), ~24.55% and ~35% of C20 
and C110 in the nose, respectively, depos-
ited in the olfactory region. These percentages 
were then used with our data for total Ag 
deposition in the nasal cavity at T0 for C20 
and at T56 for C110 to determine how much 
of the total Ag deposition was deposited only 
in the olfactory region. The percentage of Ag 
translocation was then calculated from the 
original total Ag deposited in the olfactory 
region of the nasal cavity.
Statistical Analysis
All of the data presented here were analyzed 
using JMP 10.0.0 statistical software (SAS 
Institute Inc., Cary, NC). No outliers were 
identified, with outliers being quantified as 
how far the value was from the others using 
Grubbs’ test. The ICP-MS data were first 
tested for deviations from the normality and 
homoscedasticity (equal variance) assump-
tions of analysis of variance (ANOVA) using 
Shapiro–Wilk (on model residuals) and Levene 
tests, respectively. To achieve normal distri-
butions, data were log-transformed (log10). 
ANOVA and post hoc Tukey HSD tests were 
performed for all of the ICP-MS and particle 
number data to determine specific significant 
differences between treatment groups. These 
tests were performed using a significance level 
of p < 0.05. Significance for microglial activa-
tion was determined by ANOVA and least 
significant difference (LSD) Student’s t-test to 
determine significant differences (p < 0.05) at 
each time point resulting from exposure type 
(C20 or C110 vs. control).
Results
Particle Characterization and 
Aerosolization
AgNP characteristics were determined by 
Anderson et al. (2015) and are summarized 
in Table 1. Anderson et al. (2015) observed 
minimal changes in the hydrodynamic diameter 
of AgNP determined by dynamic light scat-
tering (DLS) in suspension before (from 
sealed containers) and after exposure (from 
the nebulizer). Particle mass concentration 
from the generated aerosols was determined 
gravimetrically. In addition, airborne particle 
number concentrations were estimated using 
the XRF-determined silver mass concentrations 
(Anderson et al. 2015) (Table 1).
Silver Content in the Nasal 
Epithelium and OB
The limit of detection (LOD) was 11 ppb, 
with all data reported as measured values 
without regard to the LOD. Silver concentra-
tions in the nasal epithelia of rats exposed to 
Figure 1. Microglial morphology of rat olfactory bulb stained with anti-Iba1 antibody. Left, resting/ramified 
(R) microglia exhibiting thin, highly branched protrusions extending from the cell body; right, activated 
microglia (A) exhibiting amoeboid morphology with shorter, stouter processes. Left, rat treated with 
110-nm silver nanoparticles 21 days post-exposure; right, rat treated with 20-nm silver nanoparticles 
21 days post-exposure. Bar = 20 μm.
Table 1. Characterization of 20- and 110-nm silver nanoparticles (C20 and C110, respectively) in suspen-
sion and following aerosolization (adapted from Anderson et al. 2015).
Parameter Method C20 C110
Hydrodynamic diameter before exposure (nm)a Dynamic light scattering (DLS) 27.06 ± 0.15 111.2 ± 0.2
Hydrodynamic diameter after exposure (nm)a Dynamic light scattering 27.24 ± 0.21 106.6 ± 0.2
Geometric mean size [nm (standard deviation)] Size mobility particle scanning 77.4 (1.8) 78.2 (1.8)
Total particle mass concentration (mg/m3) Gravimetric analysis 13.9 ± 2.3 12.4 ± 2.5
Airborne silver ion concentration (mg/m3) X-ray fluorescence 7.2 ± 0.8  5.3 ± 1.0
Airborne particle number based on airborne 
concentration of silver (number/m3)b
Calculated 1.63 × 1014 7.24 × 1011
aHydrodynamic diameter of particles was measured from sealed containers before exposure and from particles 
 recovered from the nebulizer at the end of exposure. Dynamic light scattering was performed using a Zetasizer 
Nanosizer ZEN 1690.
bAirborne particle number = Airborne concentration from X-ray fluorescence (milligrams/cubic meter)/[mass of C20 or 
C110 (grams) × 1,000].
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both C20 and C110 were significantly higher 
than those in controls at all time points post-
exposure (Figure 2A). For both particle sizes, 
concentrations were highest immediately 
after treatment (T0) and lowest at T56, with 
significantly lower concentrations relative to 
T0 for C20 at T1, T21, and T56 and for 
C110 at T21 and T56. Although some data 
points are below the detection limit (citrate 
buffer, C20 at T1–T56, and C110 at T0–
T1), if viewed as measured, the trends show 
that after exposure to C20 (vs. control), 
~4% (0.013 μg/g in the OB at T0 after C20 
exposure vs. 0.34 μg/g in the nasal epithe-
lium at T0 after C20 exposure) of the Ag 
was translocated from the nose to the OB, 
and the concentration of silver detected in 
the OB at T0 (0.013 ± 0.0042) was signifi-
cantly higher than the concentration in 
controls (Figure 2B). At subsequent time 
points after C20 exposure, the concentration 
of silver in the OB of treated animals was 
not significantly different from background 
levels in controls. In contrast, the concen-
tration of silver in the OB was significantly 
higher than the T0 concentration in C110-
exposed animals at all subsequent time points 
(Figure 2B). Silver detection via autometal-
lography showed very sparse amounts only 
in C20-exposed animals at T0. Other levels 
and time points failed to clearly show Ag ions 
or particles.
Microglial Activation and 
Cytokine Expression
Microglial morphology in the OB was 
observed and differentiated between resting 
and activated states in order to determine 
whether the two AgNP types elicited responses 
(Figure 1). Compared with controls, propor-
tions of activated microglia in the OB were 
significantly higher among C20-treated 
animals at T0, T1, and T7, and in C110-
treated animals at T0 (see Table S1 for values 
in individual animals and Figure 3 for mean 
values). The mean proportion of activated 
microglia after C20 exposure decreased after 
T1 such that proportions were not significantly 
different from control animals at T21 and 
T56 and were significantly higher at T0 and 
T1 than at T56, when the mean proportion 
of activated microglia was only 3% higher (± 
12%) than the mean in controls. Conversely, 
C110 produced a variable pattern, with 
minimal activation at T1 and T7 (11% ± 11% 
and 10% ± 2%, respectively), in contrast to 
a relatively high degree of microglial activa-
tion at T0, T21, and T56 (37% ± 5%, 
34% ± 5%, and 31% ± 1%, respectively) with 
significance shown only at T0 (Figure 3). The 
mean microglial number/field was significantly 
lower than in controls for C20 animals at T0, 
suggesting a transient cytotoxic response to 
nanoparticles in the OB (Figure 4). Although 
the mean microglial number/field at T0 was 
lower in C110 animals than in controls, the 
difference was not significant, and there were 
no significant differences from controls at any 
other remaining time point for either AgNP 
exposure group.
TNF-α staining, although observed in 
the OB, was not found to be significantly 
different from that of the controls at any 
time point for either treatment group (data 
not shown).
Silver Transport to the Olfactory 
Bulb via the Olfactory Region
The amount of Ag deposited in the olfactory 
region of the nose was 0.08 μg Ag/g tissue 
and 0.15 μg Ag/g tissue for C20 and C110, 
respectively. The percentages of silver trans-
located to the OB from the olfactory region 
of the nose were 16% and 9% at T0 for C20 
and at T56 for C110, respectively.
Discussion
Short-term inhalation of AgNP resulted in 
the accumulation of silver in the OB over 
time, with some differences according to 
nanoparticle size. Following a single 6-hr 
inhalation exposure, C20 and C110 AgNP 
were deposited and taken up in the epithe-
lium of the nose, where they were retained 
and subsequently transported to the OB. 
Silver content in the nose and OB was 
monitored for up to 56 days (8 weeks) post-
exposure and correlated to varying degrees 
to microglial responses in the OB. These 
findings suggest that a) AgNP size does not 
affect retention/clearance of Ag in the nose or 
OB; b) C20 AgNP readily translocate to the 
OB, where they elicit an immediate response; 
and c) C110 AgNP accumulate and elicit a 
varied response in the OB immediately after 
exposure and at later time points.
Irrespective of the original particle size, Ag 
concentrations in the nose remained signifi-
cantly higher than in controls ≤ 8 weeks post-
inhalation. We believe that this persistence 
is most likely due to interstitial and/or intra-
epithelial localization, as was previously noted 
in the lungs of animals exposed to the same 
Figure 2. Comparison of silver concentration in the nose (A) and olfactory bulb (B) between citrate 
(control) and 20- and 110-nm silver nanoparticles (AgNP) at different post-exposure days. *Significantly 
different from citrate control (p < 0.05). #Significantly different from the mean value at T0 in animals that 
had the same exposure (p < 0.05). Values are the mean ± SE. The level of detection is 0.011 μg Ag/g tissue. 
The mean value was obtained from 5 animals per particle type and time point.
Figure 3. Comparison of percent difference from 
control of activated microglia in the olfactory 
bulb between 20- and 110-nm silver nanopar-
ticles at different post-exposure days. *Significantly 
d i f ferent  f rom ci t rate control  (p   <   0 .05) . 
#Significantly different from the mean value at post- 
exposure day 56 (T56) in animals that had the same 
exposure (p < 0.05). Values are the mean ± SE. 
The mean value was obtained from 3 animals per 
particle type and time point except for the group 
treated with 110-nm silver nano particles at T56, 
where the mean value was obtained from 2 animals.
Figure  4. Comparison of microglial number/10 
fields in the olfactory bulb between controls and 
rats exposed to silver nanoparticles at different 
post-exposure days. Values are the mean ± SE. 
The mean value was obtained from 3 animals per 
particle type and time point except for the group 
treated with 110-nm silver nanoparticles at post-
exposure day 56, where the mean value was 
obtained from 2 animals.
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treatments (Anderson et al. 2015). However, 
in the present study, autometallography failed 
to conclusively demonstrate the precise local-
ization of Ag in the nose, perhaps owing to 
the relatively small amounts of Ag remaining 
there compared with those in the lung. Ag in 
the nasal cavity can be cleared from the respi-
ratory tract via several pathways: a) mucocil-
liary movement to the nasopharynx and into 
the gastrointestinal tract; b) translocation to 
the circulatory system; c) translocation to the 
lymphatic system; and d) translocation to the 
OB. We observed significant Ag in the OB 
at T0 for C20 and at T21 and T56 for C110 
compared with controls, suggesting that Ag is 
transported from the nose to the OB.
Previous studies have reported transport 
of nanoparticles to the OB via the olfactory 
system in the nose (Elder et al. 2009; Hopkins 
et al. 2014; Oberdörster et al. 2004) as well as 
higher levels of Ag in the OB than in the rest 
of the brain as measured by atomic absorption 
spectroscopy (Ji et al. 2007; Sung et al. 2009). 
Genter et al. (2012) visualized Ag in the OB 
and in cells lining the lateral ventricle via auto-
metallography following intranasal administra-
tion and surmised that high Ag deposition in 
the OB, which is located closer to the inhala-
tion site than the rest of the brain, suggests 
that Ag particles reach the brain via the nose. 
The investigators showed aggregation of Ag in 
the turbinated areas of the nasal cavity lined 
with olfactory epithelium, which is one of the 
main direct portals of entry to the OB (Genter 
et al. 2012).
Garcia and Kimbell (2009) reported 
that even though total nasal deposition (of 
inhaled 1- to 100-nm particles) decreased with 
increasing particle size, a higher proportion 
of larger nanoparticles deposited in the olfac-
tory region than in other regions (i.e., respira-
tory, squamous, and transitional epithelium) 
of the nasal cavity. Using the computational 
fluid dynamics model proposed by Garcia 
and Kimbell (2009), we estimated that olfac-
tory deposition of C20 and C110 would be 
~25% and ~35% of the total nasal deposi-
tion, respectively. Based on this information 
and on known Ag concentration determined 
by ICP-MS, ~16% of C20 was translocated 
by T0 and ~9% of C110 was translocated 
by T56 from the olfactory region of the nose 
to the OB of the brain (see Table S2). These 
estimates are similar to those reported by 
Oberdörster et al. (2004), who showed consis-
tent accumulation of 36-nm 13C (carbon 
particles) and approximately 20% transloca-
tion from the olfactory region to the OB. In 
the study by Oberdörster et al., axonal trans-
port via the olfactory sensory neurons was the 
main translocation pathway over the 7-day 
post-exposure period.
We believe that the physicochemical 
properties (size and dissolution rate) of C20 
and C110 are most likely responsible for 
their different deposition in the OB over 
time. Although C20 AgNP are small enough 
to be rapidly transported through the olfac-
tory axons, C110 AgNP are not. Mistry et al. 
(2009a) showed that 100-nm polystyrene 
nanoparticles could not translocate from the 
olfactory axon, which tapers off through the 
basement membrane, to the OB in mice. 
Based on a previous publication reporting that 
rabbit olfactory axons have an average diameter 
of ~200 nm and that many axons have diame-
ters < 100 nm (De Lorenzo 1960; Mistry et al. 
2009b), we surmise that the average diameter 
of rat olfactory sensory neurons is likely 
≤ 100 nm. Although it is unknown whether 
Ag present in the OB is ionic or particulate, 
we speculate that Ag from C110 did not 
travel from the nose to the OB by olfac-
tory sensory neuron transport because solid 
110-nm particles are unlikely to “fit” in the 
axons. However, if the diameter of rat olfactory 
axons is > 100 nm, it may be possible for C110 
AgNP to transport (slow anterograde) from the 
nose to the OB. In this case, transport favors 
dissolved Ag ions or smaller AgNP formed 
after the initial  dissolution event.
Differences in OB Ag content at various 
time points after exposure to C20 (vs. C110) 
may be attributable to the ability of C20 to 
directly transport along the axons and to 
dissolve relatively quickly. Rapid ion dissolu-
tion is enabled by the presence of organic 
molecules (Loza et al. 2014) and by oxidation 
(Liu et al. 2012). Mucin in the nose consists 
of carbohydrates and heavily glycosylated 
proteins rich in serine and threonine residues 
(Thornton et al. 2008), which can aid in 
particle dissolution, and the nose is a contin-
uous site of oxidation. Particle size can also 
contribute to dissolution, with smaller citrate-
coated C20 undergoing faster dissolution 
than larger C110 (Wang et al. 2014; Zhang 
et al. 2011). Whereas C20 may immediately 
dissolve to form Ag+ and, in subsequent ionic 
reactions, form smaller AgNP, C110 sheds 
continuously, as evidenced by concurrent 
high concentrations of Ag+ around the parent 
AgNP over time (Davidson et al. 2015). 
C20 could be rapidly transported to the OB 
with the highest deposition occurring at the 
earliest time point (T0). In contrast, owing to 
a slower dissolution process, C110 may not 
reach the OB until approximately 21 days 
after exposure because C110 produces more 
Ag+ ions that continuously go through 
cycles of small-particle formation and disso-
lution until the parent AgNP are depleted 
(Davidson et al. 2015). Thus, the time for 
transport and accumulation of C110 Ag in 
the OB is extended.
Previous studies confirmed the presence 
of Ag in the OB with no observable histo-
pathology (Genter et al 2012; Ji et al. 2007; 
Sung et al 2009). Only Genter et al. (2012) 
examined microglial activation resulting 
from Ag exposure: three groups of mice were 
exposed to sterile water or to different doses 
of 25-nm AgNP and were sacrificed at 1 or 
7 day(s) after a single intranasal instillation. 
Despite detection of Ag in the OB, no inflam-
matory cell infiltrates or microglial activa-
tion was observed. The Genter et al. (2012) 
study and our study differ by AgNP coating. 
Whereas we coated the AgNP with citrate to 
prevent aggregation, Genter et al. (2012) did 
not and observed (by DLS) agglomeration of 
the 25-nm AgNP into 118-nm aggregates. 
This aggregation could have hindered the 
release of Ag+ for > 7 days, thereby preventing 
the observation of microglial activation. 
Indeed, the present study suggests that larger 
(C110) AgNP do not produce a significant 
amount of Ag+ immediately following deposi-
tion given that a significant amount of silver in 
the OB was only found 21 days post-exposure.
In this study, microglial activation was 
observed as an initial response. Although 
microglial activation can be beneficial to 
cellular maintenance and clearance of foreign 
substances, if prolonged and over-stimulated, 
this process can be detrimental owing to the 
release of toxic factors, such as free radicals, 
and to the potentiation of neuronal loss and 
damage (Block et al. 2007). After exposure to 
C20, animals had a significantly lower mean 
total microglial number than that in controls 
(T0; Figure 4), and the proportion of acti-
vated microglial cells was significantly higher 
than in controls at T0 and T1, but it was 
comparable to controls by T56 (Figure 3). 
Exposure to C110 produced the highest 
microglial activation at T0 that then declined 
by T7 and increased again (nonsignificantly) 
at T21 and T56. However, no significant 
differences in TNF-α staining were noted 
between treatment and control groups at any 
time point, suggesting the lack of a robust 
proinflammatory cytokine response during 
microglial activation in this study.
The microglial activation observed here 
may be caused by Ag+. A correlation has been 
noted between toxicity and dissolution of Ag+ 
from AgNP in vitro (Brett 2006; Chernousova 
and Epple 2013; Wang et al. 2014). The faster 
dissolution rate of C20 could explain the 
higher activation of microglia at earlier (vs. 
later) time points (T0 and T1). Discrepancies 
between the amount of Ag deposition and 
microglial activation after exposure to C110 
may be explained by a slower Ag+ produc-
tion rate by the larger AgNP. Although the 
presence of Ag in the OB may have been too 
low to detect at T0, trace amounts of Ag+ 
could cause microglial activation. By T1, 
Ag+ could also reduce and reform into small 
AgNP, making Ag+ unavailable to elicit a 
response. Because AgNP continuously shed 
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Ag+ until their depletion, T56 could be the 
time when these Ag+ ions are most present, 
thus causing higher microglial activa-
tion at this time point. A previous study by 
Söderstjerna et al. (2014) showed microglial 
activation in cultured neural retina explants 
resulting from exposure to 20- or 80-nm 
AgNP at final concentrations of 0.0035 and 
0.22 μg/mL, respectively. Although 80-nm 
AgNP produced significant numbers of 
activated microglia compared with controls, 
20-nm AgNP produced a nonsignificant 
elevation. To the best of our knowledge, there 
are no other reports demonstrating microglial 
activation by AgNP.
Conclusion
This study is the first to demonstrate the 
ability of Ag (from two different-sized AgNP)
to be deposited, translocated, and retained 
from the nose to the brain (OB) at levels 
sufficient to cause microglial activation for 
up to 56 days post-exposure following a 
single 6-hr inhalation period. The long-term 
retention of measurable Ag in the nasal cavity 
and the OB is also an important finding. 
The mechanism of microglial activation, the 
physico chemical state of Ag in tissues over 
time, and the potential to elicit neurological 
effects following inhalation of differently sized 
AgNP clearly merits further investigation. The 
present study provides useful information to 
increase awareness about the possible impor-
tance of regulating inhaled AgNP in occupa-
tional settings, and it demonstrates potential 
risks associated with using aerosolized AgNP 
as holistic therapeutic or antimicrobial agents.
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